Latest News and Press Releases
Want to stay updated on the latest news?
-
Santa Ana, CA., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Tipmefast, Inc. (OTC: TMEF) today announced that Lucent, Inc. (“Lucent” or the “Company”), its wholly owned subsidiary, continues to expand its role...
-
San Francisco, CA, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Kaiterra, a global leader in cutting-edge air quality monitoring solutions, announced today the launch of the Sensedge Go. This groundbreaking...
-
San Francisco, CA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Kaiterra, a global leader in cutting-edge air quality monitoring solutions, announced today the launch of the Sensedge Go. This groundbreaking...
-
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
-
Company in full commercial EV production with Class 1 and Class 3 vehicles; Bollinger Motors focused on Class 4-6 vehicles with Class 4 production starting in second half 2024 Company achieves...
-
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
-
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
-
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
-
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
-
Tübingen, Deutschland und Houston, Texas, 24. Juli 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die...